Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Braunstein on Management Strategies in Multiple Myeloma

January 7th 2021

Marc J. Braunstein, MD, PhD, discusses management strategies in multiple myeloma.

Dr. Lin on the Emergence of CAR T-Cell Therapy in Multiple Myeloma

January 7th 2021

Yi Lin, MD, PhD, discusses the emergence of CAR T-cell therapy in multiple myeloma.

Braunstein and Richter Talk Transplant and Therapy Options in Newly Diagnosed Myeloma

January 7th 2021

In our exclusive interview, Dr. Braunstein and Dr. Richter discuss navigating treatment selection for patients with the newly diagnosed multiple myeloma and the evolving role of minimal residual disease testing.

Dr. Ailawadhi on the Potential Role of Melflufen in Multiple Myeloma

January 7th 2021

Sikander Ailawadhi, MD, discusses the potential role of melflufen in multiple myeloma.

Creating a Community Improves Outcomes in Myeloma

January 6th 2021

A community can be defined by any number of characteristics. In Lonial’s case, he has built a community of physicians who’ve come together to treat patients with multiple myeloma.

Dr. Ailawadhi on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

January 5th 2021

Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.

Dr. Lin on Patient Characteristics From the CRB-401 Study of Ide-Cel in Myeloma

January 5th 2021

Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

December 23rd 2020

Dr. Lin on the Promise of Cilta-Cel and Ide-Cel in Myeloma

December 21st 2020

Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.

FDA Approval Sought for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

December 21st 2020

December 21, 2020 - A rolling submission of the biologics license application for the BCMA-directed CAR T-cell product ciltacabtagene autoleucel for use in adults with relapsed/refractory multiple myeloma has been initiated to the FDA.

Selinexor Combination Regimens Added to NCCN Guidelines for Multiple Myeloma

December 21st 2020

December 21, 2020 - The National Comprehensive Cancer Network has added 3 selinexor combination regimens to its Clinical Practice Guidelines in Oncology for previously treated patients with multiple myeloma.

FDA Approves Selinexor Plus Bortezomib/Dexamethasone for Multiple Myeloma Following 1 Prior Therapy

December 18th 2020

December 18, 2020 - The FDA has approved selinexor in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 previous therapy.

The Rationale for Targeting BCMA in Multiple Myeloma

December 18th 2020

Treatment Approach for R/R Multiple Myeloma

December 18th 2020

Dr. Braunstein on the Expanding Armamentarium in Multiple Myeloma

December 18th 2020

Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.

Dr. Rifkin on Corneal Toxicities With Belantamab Mafodotin in Multiple Myeloma

December 17th 2020

Robert M. Rifkin, MD, FACP, discusses corneal toxicities with belantamab mafodotin-blmf in multiple myeloma.

Dr. Mohyuddin on Improving Survival in Multiple Myeloma

December 17th 2020

Ghulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.

Dr. Samur on the Evolving Treatment Landscape in Multiple Myeloma

December 16th 2020

Mehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.

Dr. Shah on the Importance of Assessing Quality of Life in Multiple Myeloma

December 15th 2020

Nina Shah, MD, discusses the importance of assessing quality of life in multiple myeloma.

Dr. Stadtmauer on the Evolving Treatment Landscape in Multiple Myeloma

December 9th 2020

Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.